A Purposeful, Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis
Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections.
Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.
To combat the rapidly growing global problem of drug-resistant bacterial infections, Armata is using its proprietary bacteriophage-based technology.
Armata is headquartered in Los Angeles, California, in a 56,000 square foot facility built for phage product development with capabilities spanning bench to clinic. Microbiologists, dedicated to the discovery of natural phages, are complemented by a team of scientists that harness the natural power and diversity of these phages through synthetic biology and engineering. In-house formulation development allows tailoring of the drug product to an indication, and Armata’s in-house cGMP drug manufacturing suites and Quality Unit (QA/QC) enable the production, testing and release of clinical trial material. All of this is embedded in a seasoned team of professionals with extensive clinical development experience.
See what scientists worldwide are saying about antibiotic resistance »